Edition:
United States

Medivir AB (MVIRb.ST)

MVIRb.ST on Stockholm Stock Exchange

61.50SEK
21 Sep 2017
Change (% chg)

0.00kr (+0.00%)
Prev Close
61.50kr
Open
61.75kr
Day's High
62.00kr
Day's Low
61.50kr
Volume
816
Avg. Vol
27,466
52-wk High
102.00kr
52-wk Low
59.50kr

Chart for

About

Medivir AB is a Sweden-based pharmaceutical company engaged in the research, development and sale of drugs against widespread diseases, with protease and polymerase as its target enzymes. The Company’s research focuses on developing small molecule pharmaceuticals, primarily against infectious diseases caused by viruses. The... (more)

Overall

Beta: 1.22
Market Cap(Mil.): kr1,220.42
Shares Outstanding(Mil.): 19.84
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 80.38 16.25
EPS (TTM): -- -- --
ROI: -- 2.96 14.87
ROE: -- 4.74 13.89

BRIEF-Medivir: Janssen discontinues development of JNJ-4178 for hepatitis C

* Medivir announces Janssen to discontinue development of JNJ-4178 for hepatitis C

Sep 11 2017

BRIEF-Medivir initiates clinical study of birinapant in combination with keytruda in patients with treatment-refractory solid tumours

* Medivir initiates clinical study of birinapant in combination with keytruda® (pembrolizumab) in patients with treatment-refractory solid tumours Source text for Eikon: Further company coverage: (Reporting by Stockholm Newsroom)

Aug 18 2017

BRIEF-Medivir Q2 EBITDA loss widens

* Says net turnover for continuing operations totalled SEK 9.5 million (36.9 m), SEK 7.7 million (24.2 m) of which comprised Q2's royalties for simeprevir

Jul 25 2017

BRIEF-Stendorren Fastigheter extends strategic lease with Medivir

* NEW LEASE AGREEMENT RUNS FOR 10 YEARS FROM 2019 WITH ANNUAL RENTAL VALUE AT ABOUT SEK 5.65 MILLION

Jun 29 2017

BRIEF-Medivir says CFO Ola Burmark to step down

* Medivir's CFO Ola Burmark will leave his position - successor recruitment underway

May 30 2017

BRIEF-Medivir Q1 operating loss widens

* Q1 net turnover for continuing operations SEK 17.8 million (20.6), SEK 13.7 million (18.1) of which comprised Q1's royalties for simeprevir

Apr 28 2017

BRIEF-Medivir starts new combination study on simeprevir

* Update on the development of simeprevir as part of the triple combination with al-335 and odalasvir (jnj-4178)

Apr 24 2017

BRIEF-Medivir announces positive phase II study data, shares rise

* Says announces positive data from the phase II study of remetinostat in patients with early-stage cutaneous T-cell lymphoma

Apr 07 2017

Earnings vs. Estimates